Rinvoq
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Rinvoq in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Rinvoq.
39
Global Revenue Ranking
11
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Rinvoq
Around 700,000 people in the US are living with some form of the autoimmune disease
The drug could allow patients to taper off steroids and achieve sustained remission
The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population
An estimated 10% of adults and 24.6% of adolescents are affected by the inflammatory skin condition
The long-term inflammatory skin condition affects an estimated 1% of the global population
Inflammatory bowel disease affects nearly one in every 100 people in the US
It is estimated that over 155,000 adults are living with the condition in the UK
Inflammatory bowel disease affects nearly one in every 100 people in the US
The therapy is now the first oral JAK inhibitor authorised to treat this patient population
Over 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms
In Scotland, there are around 44,000 people living with the progressive autoimmune disease
The recommendation is for adults living with the condition in England and Wales
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology